In 2018, Johnson & Johnson launched a mission to revolutionize the study of blood clots. The company aimed to investigate how various clot characteristics, such as size, composition, and density, could impact patient outcomes. Additionally, they wanted to evaluate the effectiveness of two of their medical devices in removing blood clots.
To accomplish this goal, Johnson & Johnson conducted a study known as the Excellent Registry. This study involved enrolling 1,000 stroke patients at 36 clinical trial sites around the world to analyze actual blood clots that had been removed from stroke patients.
The Excellent Registry is the largest acute ischemic stroke registry globally and collects patient data, imaging, and clot information on a per-pass basis. Independent evaluators review the data to ensure accuracy and objectivity. This initiative underscores Johnson & Johnson’s commitment to innovation and advancing stroke care.
Given the alarming statistics that every 40 seconds someone in the United States has a stroke and every 3.5 minutes someone dies from one, Johnson & Johnson’s dedication to improving stroke care is crucial. For more information from Johnson & Johnson, click here.
